Dr. Reddy’s Launches Generic Secondary Hyperparathyroidism Treatment Injection In U.S.
Pharmaceutical major Dr. Reddy's Laboratories Ltd. on Friday said it has launched generic Doxercalciferol injection used for treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis in the U.S. market.
The company has launched Doxercalciferol injection, 4 mcg/2 ml (2 mcg/ml) multiple-dose vials is approved by the United States Food and Drug Administration, Dr. Reddy's Laboratories said in a filing to the BSE.
The product is generic version of Sanofi-Aventis U.S. LLC's Hectorol injection in the same strength, multiple-dose vials, it added.
According to IQVIA Health data, "Hectorol injection 4 mcg/2 ml (2 mcg/ml) single-dose vials and multiple-dose vials brand and generics had US sales of around $138 million MAT for the most recent 12 months ending in September 2019," Dr. Reddy's said.
Shares of Dr. Reddy's Laboratories on Friday closed at Rs 2,866.80 per scrip on the BSE, down 0.43 percent from its previous close.